An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
about
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and MassChronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic conditionIncreased Serum Insulin Exposure Does Not Affect Age or Stage of Pancreatic Adenocarcinoma Diagnosis in Patients With Diabetes Mellitus.Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.An updated review on cancer risk associated with incretin mimetics and enhancers.Safety of antidiabetes medications: An update.Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!GLP-1 based therapies: clinical implications for gastroenterologists.Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.Incretin-based therapies: facing the realities of benefits versus side effects.The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.Effects of Linagliptin on Pancreatic α Cells of Type 1 Diabetic Mice.Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.
P2860
Q26749089-70DAD96A-CE6E-4511-8D6C-5AEC335C6E20Q34780873-E53310E9-F42B-4574-A7F6-BAA9DF3EC826Q35184904-89250865-4C14-498C-B4E4-6DE8FA8C8800Q36456052-4B5F1F1B-67F5-40A4-9914-CFA7DFE2EF01Q37402786-1C42C0DB-D785-4A3D-955E-214DCFB01165Q38264360-05945A41-07CF-44D3-B4ED-B9C42F0FC4B5Q38388920-D24AF3CB-A66A-4BC7-A030-A88841CA0825Q38395221-C11FBD52-F282-455B-B0AF-1A7D38AB49F1Q38601929-F2E536FF-AB02-46A1-B881-867C2AEAC67FQ38703292-08DE03A8-36D1-478A-906D-DDEEE8C58BF3Q39017198-E0491EAB-85AD-41EB-841E-900CE432CA53Q41465810-2921F524-4B91-4537-B52E-90F41A49CCBBQ42921290-E7FC3198-C9AC-46F7-AD75-041E7B805EEEQ45778975-93F1D22F-9447-4822-9063-F3CDCBB849EFQ47096196-70A25E9D-B925-48D5-AA17-2F8D336614EEQ52741508-766A2AC6-75FC-4657-BF98-8AA803A3F802Q52780711-AAA4F91D-317F-4E0D-8F97-8BF56E399CB0
P2860
An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
An analysis of characteristics ...... fects on pancreatic pathology.
@en
type
label
An analysis of characteristics ...... fects on pancreatic pathology.
@en
prefLabel
An analysis of characteristics ...... fects on pancreatic pathology.
@en
P2093
P356
P1476
An analysis of characteristics ...... fects on pancreatic pathology.
@en
P2093
Evis Harja
Jay S Skyler
Jonathan Lord
P304
P356
10.1089/DIA.2013.0177
P577
2013-08-08T00:00:00Z